The Memorial Sloan Kettering Cancer Center SPORE in Pancreas Cancer

纪念斯隆凯特琳癌症中心胰腺癌孢子

• 批准号: 10706975
• 负责人: Eileen Mary O'Reilly
• 金额: $ 233.61万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-20 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10706975
• 关键词: Biological Markers; Biology; Cessation of life; Clinical; Clinical Management; Clinical Research; Clinical Trials; Collaborations; Complex; Cytotoxic Chemotherapy; DNA Repair; Development; Diagnosis; Disease; Disease remission; Early Diagnosis; Epidemiology; Fluorouracil; Gene Expression Profiling; Genetic; Genomics; Goals; Image; Immune; Immune Targeting; Immune checkpoint inhibitor; Immunologics; Immunotherapy; Interleukin Activation; Investigation; Knowledge; Laboratory Research; Leucovorin; Lymphocyte Subset; Lymphoid Cell; Malignant neoplasm of pancreas; Memorial Sloan-Kettering Cancer Center; Mismatch Repair Deficiency; Modality; Molecular; Mutation; Newly Diagnosed; Outcome; PALB2 gene; Paclitaxel; Pancreas; Pancreatic Ductal Adenocarcinoma; Pathway interactions; Patient-Focused Outcomes; Patients; Phenotype; Platinum Compounds; Poly(ADP-ribose) Polymerase Inhibitor; Poly(ADP-ribose) Polymerases; Public Health; Research; Resistance; Specialized Program of Research Excellence; Symptoms; Therapeutic; Tissues; Translational Research; United States; biomarker development; brca gene; checkpoint therapy; cytotoxic; experience; gemcitabine; gene repair; immune cell infiltrate; immune checkpoint blockade; immunogenic; improved; improved outcome; ineffective therapies; innovation; insight; irinotecan; molecular diagnostics; nanoliposome; next generation; next generation sequencing; novel; novel therapeutic intervention; novel therapeutics; pancreatic cancer patients; pancreatic neoplasm; patient subsets; prospective; repaired; response; single cell analysis; standard of care; targeted treatment; therapy resistant; treatment response; tumor; tumor-immune system interactions

PROJECT SUMMARY –OVERALL An increasing number of studies indicate that some patients with pancreas ductal adenocarcinoma (PDAC) have exceptional and durable responses to therapy, both standard of care and, more rarely to immune-based therapies. There is a unique opportunity to understand the genetic and molecular mechanisms that underlie these exceptional responses or define mechanisms of intrinsic resistance to therapy to prospectively guide clinical management and ultimately increase overall survival for all patients with pancreas cancer. We propose a Specialized Program of Research Excellence in Pancreas Cancer at Memorial Sloan Kettering Cancer Center (the MSK Pancreas SPORE) to leverage cutting-edge molecular knowledge of pancreas biology and clinical innovations to advance translational research in pancreas cancer. Our long-term translational objective is to demonstrate that prospective, next-generation molecular approaches combined with state-of-the-art clinical management can improve outcomes of patients with pancreas malignancies. We will specifically focus on the most challenging disease settings, locally advanced and metastatic PDAC, where the clinical needs are most profound. To achieve this objective, we propose three specific aims. In Aim 1, we will leverage current state-of- the-art and novel therapies to improve outcomes for patients with stage III and IV PDAC by building upon recent developments in cytotoxic and targeted therapies and apply these agents and combinations in novel disease settings. In Aim 2, we will apply innovation in molecular characterization of PDAC to drive clinical management by building upon our extensive expertise in imaging, molecular diagnostics, biomarker development, and single- cell analyses to develop and validate prospective biomarkers of treatment response and resistance. In Aim 3, we will investigate two avenues of surmounting intrinsic immunotherapy resistance in PDAC: synthetic lethality of combination PARP inhibition and immune checkpoint blockade, and via activation of the interleukin-33 – group 2 innate lymphoid cell (IL33-ILC2) axis. We expect that successful completion of these aims will provide new insights into PDAC biology, establish new collaborations, alter treatment paradigms, and ultimately improve disease-free and overall survival in pancreas cancer.

项目总结--总体 越来越多的研究表明，一些胰腺导管腺癌(PDAC)患者 对治疗的特殊和持久的反应，既有标准的护理，也有更少的基于免疫的反应 治疗。有一个独特的机会来了解其背后的遗传和分子机制。 这些特殊的反应或定义了治疗的内在抵抗机制，以前瞻性地指导 临床管理，并最终提高所有胰腺癌患者的总存活率。我们建议 纪念斯隆-凯特琳癌症中心胰腺癌卓越研究专业项目 (MSK胰腺孢子)利用胰腺生物学和临床的前沿分子知识 推进胰腺癌转化研究的创新。我们的长期翻译目标是 展示了未来的下一代分子方法与最先进的临床相结合 治疗可以改善胰腺恶性肿瘤患者的预后。我们将特别关注 最具挑战性的疾病环境，局部晚期和转移性PDAC，临床需求最大的地方 很深刻。为了实现这一目标，我们提出了三个具体目标。在目标1中，我们将利用当前状态- -ART和新疗法通过建立在最近的基础上，改善III和IV期PDAC患者的预后 细胞毒和靶向治疗的进展及其在新疾病中的应用 设置。在目标2中，我们将应用PDAC分子表征方面的创新来推动临床管理 凭借我们在成像、分子诊断、生物标记物开发和单项技术方面的广泛专业知识， 细胞分析，以开发和验证治疗反应和耐药性的预期生物标志物。在《目标3》中， 我们将探讨克服PDAC固有免疫治疗耐药性的两种途径：合成致死性 通过联合抑制PARP和免疫检查点阻断，并通过激活白细胞介素33-基团 2固有淋巴样细胞(IL33-ILC2)轴。我们期待着这些目标的成功实现将提供新的 洞察PDAC生物学，建立新的合作，改变治疗范例，并最终改进 胰腺癌的无病生存率和总存活率。